Crossmark

Large-scale pharmacogenomics based drug discovery for ITGB3 dependent chemoresistance in mesenchymal lung cancer

Crossref DOI link: https://doi.org/10.1186/s12943-018-0924-8

Published Online: 2018-12-18

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hong, Soon-Ki

Lee, Haeseung

Kwon, Ok-Seon

Song, Na-Young

Lee, Hyo-Ju

Kang, Seungmin

Kim, Jeong-Hwan

Kim, Mirang

Kim, Wankyu

Cha, Hyuk-Jin https://orcid.org/0000-0001-9277-2662
Funding

Funding for this research was provided by:

National Research Foundation of Korea (2017M3C9A5028691)

National Research Foundation of Korea (2017M3A9B3061843, 2017R1A6A3A11030794)
License Information

Text and Data Mining valid from 2018-12-01
More Information

Article History

Received: 11 July 2018

Accepted: 30 November 2018

First Online: 18 December 2018

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.